Vivodyne Opens Human Data Center After Raising Nearly $80 Million for AI Drug Discovery
Updated
Updated · TechCrunch · Aug 19
Vivodyne Opens Human Data Center After Raising Nearly $80 Million for AI Drug Discovery
2 articles · Updated · TechCrunch · Aug 19
Summary
Just outside San Francisco, Vivodyne has opened what it calls the world’s largest “human data center,” using HIVE robotic labs to grow 20 human tissue types and run autonomous dosing and monitoring experiments.
The startup says AI drug discovery lacks causal data from living human tissue, leaving models trained mostly on animal tests or static cell snapshots that fail to capture how biological states change.
90% of drugs that work in animal testing still fail to win approval after entering human trials, a gap Vivodyne says its platform can narrow before companies spend tens of millions of dollars on clinical studies.
94% liver-toxicity predictive accuracy, 96% airway-tissue matching and 100% concordance in 20 chemotherapy-drug bone marrow tests underpin Vivodyne’s pitch to major pharma partners it has not named publicly.
Nearly $80 million in funding and throughput Vivodyne says already exceeds all U.S. animal trials combined by 2 times support its broader goal: training AI models on causal human-biology data for more reliable drug discovery.
If biology has no internet, will Vivodyne’s massive human data centers finally teach AI to cure diseases that animal testing missed?
With millions of automated experiments, can lab-grown tissues truly replace the complex systemic responses of living organisms in future clinical trials?